The Effect of Endometrial Stem Cells with Pomalidomide on Serum Glutathione and Lipids in 6-OHDA Induced Rat Model of Parkinson

Subject Areas : Journal of Animal Biology

Elham Ghasemi deligani ¹ , Maryam Khosravi ² , Mahmoud Salami Zavareh ³ , Ramin Haji Khani ⁴

1 - Department of Biology, Islamic Azad University, North-Tehran Branch, Tehran, Iran
2 - Department of Biology, Islamic Azad University, North-Tehran Branch, Tehran, Iran
3 - Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
4 - Department of Biology, Islamic Azad University, North-Tehran Branch, Tehran, Iran

Received: 2021-09-04 Accepted : 2021-10-30 Published : 2022-08-23

Keywords: Glutathione, Parkinson, Pomalidomide, 6-Hydroxydopamine, endometrial stem cells, Low Density Lipoprotein,

Abstract :

Parkinson’s disease is the second most common age-related neurodegenerative disease with no identified effective treatment. The aim of this study was to evaluate the effects of human endometrial stem cells with the anti-inflammatory drug pomalidomide on glutathione (GSH) and serum lipids (total cholesterol,TC and low density lipoprotein, LDL)) in the Parkinson’s model in male Wistar rats. Male rats were randomly assigned to five groups (8 animals in each group) including: control, Parkinson’s, and 3 experimental Parkinson’s groups receiving stem cells, pomalidomide, and a combination of stem cells and pomalidomide. Parkinson’s was induced by injection of 6-hydroxy dopamine (concentration 6 μg) in the striatum by stereotaxic method. In the fourth week after surgery, the three experimental groups were treated with  4 mg/kg/daily of pomalidomide, 100,000  stem cells through intranasal route, and a combination of pomalidomide at a dose of 4 mg/kg/daily and 100,000 stem cells. At the end of day 28, blood samples were taken from the groups and factors were measured. The results revealed a significant increase in glutathione among the treated groups compared to the Parkinson’s group. There was also a significant decrease in glutathione in Parkinson’s group compared to the control group. Comparison between Parkinson’s group and the group treated with pomalidomide and endometrial stem cells showed a significant reduction in cholesterol. Moreover, LDL levels showed a significant decrease in LDL levels in the treated groups compared to the Parkinson’s group. Considering the improvement of the measured factors in Parkinson’s rat, allogeneic stem cells can be used as a potential source along with pomalidomide in future research for the treatment of Parkinson’s disease.

References:

1. Adibhatla R.M., Hatcher J.F. 2007. Role of lipids in brain injury and diseases. Future lipidology, 2(4): 403-422.


2. Ai J., Shahverdi A.R., Barough S.E., Kouchesfehani H.M., Heidari S. Derivation of adipocytes from human endometrial stem cells (EnSCs). Journal of Reproduction and Infertility, 13(3): 151.


3. Andican G., Konukoglu D., Bozluolcay M., Bayülkem K., Firtiına S., Burcak G. 2012. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease. Acta Neurologica Belg., 112(2): 155-159.


4. Bagheri-Mohammadi S., Alani B., Karimian M., Moradian-Tehrani R., Noureddini M. 2019. Intranasal administration of endometrial mesenchymal stem cells as a suitable approach for Parkinson’s disease therapy. Molecular Biology and Reproduction, 46(4): 4293-4302.


5. Bagheri‐Mohammadi S., Karimian M., Alani B., Verdi J., Tehrani R.M. 2019. Stem cell‐based therapy for Parkinson’s disease with a focus on human endometrium‐derived mesenchymal stem cells. Journal of Cell Physiology, 234(2): 1326-1335.


6. da Conceição F.S., Ngo-Abdalla S., Houzel J.C., Rehen S.K. 2010. Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test. Journal of Visualized Experiments, 35: e1376.


7. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4): 315-7.


8. Duke C.M., Taylor H.S. 2013. Stem cells and the reproductive system: Historical perspective and future directions. Maturitas, 76(3): 284-289.


9. Dunnett S.B., Björklund A., Lindvall O. 2001. Cell therapy in Parkinson's disease–stop or go?. Nature Reviews Neurrology, 2(5): 365-369.


10. Fearnley J.M., Lees A.J. 1991. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114(5): 2283-2301.


11. Gregório M.L., Pinhel M.A., Sado C.L., Longo G.S., Oliveira F.N. 2013. Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson's disease. BioMedical Research International, 641515.


12. Hammond C.L., Lee T.K., Ballatori N.J. 2001. Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. Journal of Hepatolog, 34(6): 946-54.


13. Harris V.K., Stark J., Vyshkina T., Blackshear L., Joo G. 2018. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine, 29: 23-30.


14. Huang X., Auinger P., Eberly S., Oakes D., Schwarzschild M. 2011. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One, 6(8): e22854.


15. Kandel E.R., Schwartz J.H., Jessell TM., 2000. Principles of neural science. 4th ed.McGraw-hill New York.


16. Kitada M., Dezawa M. 2012. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson’s Disease, 2012: 873706.


17. Kundu S., Ghosh P., Datta S., Ghosh A., Chattopadhyay S., Chatterjee M. 2012. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radical Research, 46(12): 1482-1489.


18. Lindvall O., Kokaia Z. 2009. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends of Pharmacological Sciences, 30(5): 260-267.


19. Lindvall O., Kokaia Z. 2006. Stem cells for the treatment of neurological disorders. Nature, 441(7097): 1094-1096.


20. Maria S., Helle B., Tristan L., Gaynor S., Arnar A., et al. 2013. Improved cell therapy protocol for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC and non-human primate iPSC-derived DA neurons. Stem Cells, 31(8): 1548.


21. Parmar M. 2018. Towards stem cell based therapies for Parkinson's disease. Development, 145(1): 156117.


22. Paxinos G., Watson C. 2006. The rat brain in stereotaxic coordinates: hard cover edition. Elsevier.


23. Salama M., Sobh M., Emam M., Abdalla A., Sabry D. 2017. Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease. Experimantal Therapy Medicine, 13(3): 976-982.


24. Su P., Loane C., Politis 2011. The Use of Stem Cells in the Treatment of Parkinsons Disease. Insciences Journal, 1(3): 136-156.


25. Sugiyama K., Ohishi K., Muramatsu K., Chemistry B. 1987. Effects of dietary glutathione on plasma and liver lipid levels in rats fed on a high cholesterol diet Agricultural Biological Chemistry, 51(6): 1601-1606.


26. Trupp M., Jonsson P., Öhrfelt A., Zetterberg H., Obudulu O. 2014. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. Journal of Parkinson's Disease, 4(3): 549-560.


27. Valera E., Mante M. ,Anderson S., Rockenstein E., Masliah E. 2015. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease. Journal of Neuroinflammation, 12(1): 93.


28. Wang J.Y., Huang Y.N., Chiu C.C., Tweedie D., Luo W. 2016. Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. Journal of Neuroinflammation., 13(1): 1-17.


29. Xia R., Mao Z.H. 2012. Progression of motor symptoms in Parkinson’s disease. Neuroscience Bulletin, 28(1): 39-48.